| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, California 93106 [V. K. N., K. B., D. P., M. A. J., L. W.], and Division de Cancerologie Experimentale, Centre de Recherche Pierre Fabre, 81106 Castres Cedex, France [B. T. H.]
Vinflunine is a novel Vinca alkaloid presently in Phase I clinical trials. In preclinical studies, it exhibited superior antitumor activity to that of other Vinca alkaloids, including vinorelbine from which it was synthetically derived. Vinca alkaloids appear to inhibit cell proliferation by affecting the dynamics of spindle microtubules. Here we have analyzed the effects of vinflunine and vinorelbine on microtubule dynamic instability and treadmilling and found that these newer drugs exert effects on microtubule dynamics that differ significantly from those of the classic Vinca alkaloid, vinblastine. The major effects of vinflunine and vinorelbine on dynamic instability were a slowing of the microtubule growth rate, an increase in growth duration, and a reduction in shortening duration. In marked contrast to the action of vinblastine, they neither reduced the rate of shortening nor increased the percentage of time the microtubules spent in an attenuated state, neither growing nor shortening detectably. In addition, vinflunine and vinorelbine suppressed treadmilling, but less strongly than vinblastine. The diverse actions of these drugs on microtubules are likely to produce different effects on mitotic spindle function, leading to different effects on cell cycle progression and cell killing. Nontumor cells with normal checkpoint proteins may tolerate the relatively less powerful inhibitory effects of vinflunine and vinorelbine on microtubule dynamics better than the more powerful effects of vinblastine. Thus the unique constellation of effects of vinflunine and vinorelbine on dynamic instability and treadmilling may contribute to their superior antitumor efficacies.
This article has been cited by other articles:
|
|
 |
|
  J. Bennouna, J.-P. Delord, M. Campone, and L. Nguyen Vinflunine: A New Microtubule Inhibitor Agent Clin. Cancer Res., March 15, 2008; 14(6): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pourroy, S. Honore, E. Pasquier, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res., March 15, 2006; 66(6): 3256 - 3263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stuckler, J. Singhal, S. S. Singhal, S. Yadav, Y. C. Awasthi, and S. Awasthi RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non-Small Cell Lung Cancer Cancer Res., February 1, 2005; 65(3): 991 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamaguchi, J. Chen, K. Bhalla, and H.-G. Wang Regulation of Bax Activation and Apoptotic Response to Microtubule-damaging Agents by p53 Transcription-dependent and -independent Pathways J. Biol. Chem., September 17, 2004; 279(38): 39431 - 39437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pourroy, M. Carre, S. Honore, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer Low Concentrations of Vinflunine Induce Apoptosis in Human SK-N-SH Neuroblastoma Cells through a Postmitotic G1 Arrest and a Mitochondrial Pathway Mol. Pharmacol., September 1, 2004; 66(3): 580 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okouneva, B. T. Hill, L. Wilson, and M. A. Jordan The Effects of Vinflunine, Vinorelbine, and Vinblastine on Centromere Dynamics Mol. Cancer Ther., May 1, 2003; 2(5): 427 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bennouna, P. Fumoleau, J.-P. Armand, E. Raymond, M. Campone, F.-M. Delgado, C. Puozzo, and M. Marty Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours Ann. Onc., April 1, 2003; 14(4): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Newton, J. G. DeLuca, R. H. Himes, H. P. Miller, M. A. Jordan, and L. Wilson Intrinsically Slow Dynamic Instability of HeLa Cell Microtubules in Vitro J. Biol. Chem., November 1, 2002; 277(45): 42456 - 42462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Giannakakou, M. Nakano, K. C. Nicolaou, A. O'Brate, J. Yu, M. V. Blagosklonny, U. F. Greber, and T. Fojo Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics PNAS, August 6, 2002; 99(16): 10855 - 10860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Ngan, K. Bellman, B. T. Hill, L. Wilson, and M. A. Jordan Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca Alkaloids Vinorelbine and Its Newer Derivative Vinflunine Mol. Pharmacol., July 1, 2001; 60(1): 225 - 232. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
